Eli Lilly requests for EUA approval from FDA for COVID-19 antibody
Category: #health  By Nikita Chaurasia  Date: 2020-10-09
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly requests for EUA approval from FDA for COVID-19 antibody

Eli Lilly and Company, the American pharmaceutical giant, has reportedly applied for emergency use authorization (EUA) for its potential COVID-19 antibody from the Food & Drug Administration (FDA). Sources with knowledge of the matter stated that the company has applied for EUA based on its previous study results and new information.

For those unfamiliar, Eli Lilly has developed a monoclonal antibody combination therapy called LY-CoV555 in order to treat the patients suffering from mild-to-moderate COVID-19. The company claims that its experimental antibody can help in reducing the virus level in the body as well as the overall hospitalization rates.

According to credible sources, the Phase 2 trials of the potential antibody comprised of around 112 people while up to 156 individuals were given a placebo. In this context, Eli Lilly specified that the patients who received the antibody therapy witnessed a significant decline in their virus levels after three to seven days.

Moreover, the company stated that over 0.9% of the patients on treatment went to emergency room or were hospitalized. Around 5.8% of the patients on placebo were apparently hospitalized as well.

Professor of pharmacoepidemiology at London School of Hygiene & Tropical Medicine, Stephen Evans was reported saying that although the data of phase 2 trials is encouraging, the experimental drug is still at preliminary stage. He further mentioned that the evidence derived from LY-CoV555 trials is not effective and needs to be studied more.

It is to be noted that Eli Lilly plans to produce over 1 million doses of its potential vaccine after receiving FDA authorization for its emergency use against the virus.

In other news, the FDA has reportedly informed the pharmaceutical companies to provide two months of safety data before authorizing the emergency use of their respective vaccines.

Source credits-

https://edition.cnn.com/2020/10/07/health/eli-lilly-antibody-therapy-results-eua/index.html

https://www.news18.com/news/world/u-s-fda-safety-guidelines-likely-to-push-covid-19-vaccine-authorization-past-election-2939275.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Mercedes-Benz unveils the S-Class of EVs, comes with a 56-inch display

Mercedes-Benz unveils the S-Class of EVs, comes with a 56-inch display

By Nikita Chaurasia

Mercedes-Benz, a German multinational automaker of luxury and commercial vehicles, has unveiled its flagship electric sedan, the EQS. The new vehicle is likely to allow Mercedes to take on Tesla Inc., as the market for electric vehicles (EVs) continu...

Ford takes on GM, Tesla by debuting its first hands-free driving system

Ford takes on GM, Tesla by debuting its first hands-free driving system

By Nikita Chaurasia

Ford Motor Company, the American multinational automaker, is reportedly planning on introducing a hands-free driving feature on its 2021 Mustang Models as well as 2021 F-150 pickup truck through a software update, by the end of the year. The automob...

Oculus Quest 2 update to include wireless PC streaming, 120Hz mode

Oculus Quest 2 update to include wireless PC streaming, 120Hz mode

By Nikita Chaurasia

Oculus, a subsidiary of Facebook, Inc., that develops and manufactures virtual reality headsets, has recently announced that Oculus Quest 2’s new v28 software update will include native wireless desktop PC streaming as well as 120 Hz refresh ra...